| Segment Reporting |
Segment Reporting The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases. The Company’s Chief Operating Decision Maker (the CODM) is its Chief Executive Officer. The CODM evaluates financial information on a consolidated basis for the purposes of allocating resources and assessing performance. The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2025 | | 2024 | | 2025 | | 2024 | | Total revenues | $ | 81,504 | | | $ | 30,858 | | | $ | 147,350 | | | $ | 80,427 | | Less: | | | | | | | | | Cost of sales | 6,929 | | | 3,278 | | | 12,780 | | | 6,346 | | Topical roflumilast program costs | 2,827 | | | 2,931 | | | 4,273 | | | 6,519 | | Topical JAK inhibitor program costs | 343 | | | 595 | | | 719 | | | 1,262 | | Other early-stage programs costs | 1,695 | | | 1,835 | | | 3,690 | | | 5,968 | | | Research and development compensation and personnel-related expenses | 9,779 | | | 9,362 | | | 19,417 | | | 19,740 | | | Selling, general and administrative expenses | 69,033 | | | 58,049 | | | 132,917 | | | 112,720 | | Other segment expenses(1) | 5,509 | | | 4,885 | | | 12,694 | | | 9,571 | | | Total operating expenses | 96,115 | | | 80,935 | | | 186,490 | | | 162,126 | | | Operating loss | (14,611) | | | (50,077) | | | (39,140) | | | (81,699) | | | | | | | | | | | Other income, net | 2,096 | | | 5,229 | | | 4,826 | | | 9,273 | | | Interest expense | (3,029) | | | (7,484) | | | (6,011) | | | (14,964) | | | Provision for income taxes | 342 | | | — | | | 621 | | | 324 | | | Segment and consolidated net loss | $ | (15,886) | | | $ | (52,332) | | | $ | (40,946) | | | $ | (87,714) | |
|